Back to top

Analyst Blog

Based on preliminary data, leading dental laser maker BIOLASE Technology expects revenues for the second-quarter 2011 to more than double year over year to roughly $12 million.

Sequentially, this represents a 14% growth.

The significant growth in sales were, in part, attributable to healthy demand for the company’s new WaterLase iPlus all-tissue laser (launched in January 2011), which is shaping up to be a major future growth driver. However, sales were below the consensus view of roughly $14.3 million. BIOLASE is expected to report full results in August 2011.

The California-based company also noted that it was unable to deliver roughly $2 million of orders booked in the second quarter by June 30, 2011, given a major change in order placed by dental products distributor Henry Schein (HSIC - Analyst Report), one of its key distributors. This resulted in supply chain delays.

Henry Schein originally had a pre-paid purchase order worth $9 million for BIOLASE’s iLase dental lasers but made a late change in its order to a combination of Waterlase iPlus and the ezlase laser systems.

Despite the inability to complete the shipment in the second quarter, the company maintains its expectations for fiscal 2011. BIOLASE expects to complete the shipment by the end of July 2011, well ahead of the contractual due date of August 25.

BIOLASE develops and markets lasers and related products for applications in medicine and dentistry. Its key products are dental laser systems capable of performing a broad range of dental procedures, including cosmetic and complex surgical applications. The company recently adopted a direct and multi-distributor sales model in Germany, mirroring its strategy in North America.

BIOLASE, in June 2011, opened its offices in two of the largest Asian markets: China and India. The company sees huge growth potential for its dental laser products in these lucrative markets. BIOLASE expects its direct presence in these markets to drive the adoption of its dental products by local physicians and significantly contribute to sales growth starting second-half 2011.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%